Resultados: 7

Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018

Malar. j. (Online); 20 (1), 2021
Background: Due to the threat of emerging anti-malarial resistance, the World Health Organization recommends incorporating surveillance for molecular markers of anti-malarial resistance into routine therapeutic efficacy studies (TESs). In 2018, a TES of artemether-lumefantrine (AL) and artesunate-amodiaq...

Effect of mass dihydroartemisinin-piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance

PLos ONE; 15 (10), 2020
Background Mass drug administration (MDA) can rapidly reduce the burden of Plasmodium falciparum (Pf). However, concerns remain about its contribution to select for antimalarial drug resistance. Methods We used Sanger sequencing and real-time PCR to determine the proportion of molecular markers associate...

Counter-Selection of Antimalarial Resistance Polymorphisms by Intermittent Preventive Treatment in Pregnancy

J. infect. dis; 221 (2), 2020
Background: Innovative approaches are needed to limit antimalarial resistance evolution. Understanding the role of intermittent preventive treatment in pregnancy (IPTp) on the selection for resistance and the impact such selection has on pregnancy outcomes can guide future interventions. Methods: Plasmod...

Drug-resistant polymorphisms and copy numbers in plasmodium falciparum, mozambique, 2015

One of the fundamental steps toward malaria control is the use of antimalarial drugs. The success of antimalarial treatment can be affected by the presence of drug-resistant populations of Plasmodium falciparum. To assess resistance, we used molecular methods to examine 351 P. falciparum isolates collect...

Genetic analysis and natural polymorphisms in HIV-1 gp41 isolates from Maputo City, Mozambique

AIDS res. hum. retrovir; 30 (6), 2014
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp...

Genetic Analysis and Natural Polymorphisms in HIV-1 gp41 Isolates from Maputo City, Mozambique

AIDS res. hum. retrovir; 30 (6), 2013
Enfuvirtide was the first fusion inhibitor approved by the Food and Drug Administration (FDA) in 2003 for HIV-1 infection in treatment-experienced patient. It is the first approved antiviral agent to attack the HIV life cycle in its early stages. For HIV fusion to occur, the HR1 and HR2 domains in the gp...

Análise genética por RAPD de estirpes de Schistosoma mansoni com diferente susceptibilidade à infecção no hospedeiro definiti

A schistosomose é a segunda parasitose com maior impacto na Saúde Pública afectando mais de 200 milhões de pessoas que vivem em países subdesenvolvidos das regiões tropicais e subtropicais, sendo que 85% vivem em África. Trata-se de um complexo de infecções parasitárias crónicas e agudas, caus...